The goal of this observational study is to evaluate the efficacy the favorable response rate and safety of L-AmB(liposomal amphotericin B) for the treatment of br-IFD(breakthrough invasive fungal disease) in Chinese children and adolescent patients with hematological malignancies receiving triazoles/echinocandins antifungal prophylaxis.
The main question it aims to answer is:
1. Whether the L-AmB have the same efficacy in the treatment of br-IFD in Chinese children and adolescent with hematological malignancies who are receiving triazoles or echinocandins antifungal prophylaxis as in adults(compared with historical data) 2. Whether L-AmB may have better renal safety in Chinese children and adolescent than in adults (compared with historical data).
Chinese children and adolescent with hematological malignancies will taking L-AmB as part of their regular medical care for br-IFD. The efficacy and safety data will be recorded.
The children and adolescent patients with hematological malignancy received echinocandin/triazole for antifungal prophylaxis and diagnosed with br-IFD.
Age: from 1 month to 18 years old.
Diagnosed patients with hematological malignancy.
Received echinocandin/triazole for antifungal prophylaxis at least 7 days.
(a) Received AmB formulation for prophylaxis or treatment within the past 30 days.
Institute of Hematology & Blood Diseases Hospital, China
Lead sponsor
Gilead Sciences
Collaborator